search
Back to results

IVUS-guided DES Implantation in Coronary Calcification (ULTIMATE IV)

Primary Purpose

Coronary Artery Disease

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Intravascular ultrasound
Angiography
Sponsored by
Nanjing First Hospital, Nanjing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Silent ischemia, stable or unstable angina, non-ST-segment elevation myocardial infarction > 48 hours, or ST-segment elevation myocardial infarction > 7 days; De novo coronary lesion eligible for drug-eluting stent implantation; Target lesion with severe calcification; Exclusion Criteria: Age less than 18-year-old; Comorbidity with a life expectancy <12 months; Intolerant of antithrombotic therapy; Significant anemia, thrombocytopenia, or leucopenia; History of major hemorrhage (intracranial, gastrointestinal, and so on); Chronic total occlusion lesion not recanalized; Scheduled major surgery in the next 12 months; Left ventricular ejection fraction < 25%; Uremia dependent on dialysis treatment; Previous drug-eluting stent implantation in target vessel;

Sites / Locations

  • Nanjing First HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intravascular ultrasound guidance

Angiography guidance

Arm Description

Outcomes

Primary Outcome Measures

the rate of target-vessel failure at 12 months
the composite of cardiovascular death, target-vessel myocardial infarction, and clinically driven target-vessel revascularization

Secondary Outcome Measures

Full Information

First Posted
March 23, 2023
Last Updated
April 12, 2023
Sponsor
Nanjing First Hospital, Nanjing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05800002
Brief Title
IVUS-guided DES Implantation in Coronary Calcification
Acronym
ULTIMATE IV
Official Title
Intravascular Ultrasound Versus Angiography Guided Drug-eluting Stent Implantation for Patients With Coronary Severe Calcification: a Prospective, Multicenter, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 7, 2023 (Actual)
Primary Completion Date
March 30, 2026 (Anticipated)
Study Completion Date
March 30, 2033 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanjing First Hospital, Nanjing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Coronary calcified lesion is associated with a poor clinical outcome. Intravascular ultrasound (IVUS) provides anatomic information in detail about reference vessel dimensions and lesion characteristics including severity of diameter stenosis, lesion length, and morphology. Both randomized and observational studies have reported the clinical benefits of IVUS guidance for patients with chronic total occlusion (CTO), long lesions, acute coronary syndrome (ACS) with complex bifurcation lesions. Our previous ULTIMATE trial has demonstrated that IVUS-guided drug-eluting stent (DES) implantation significantly improved clinical outcome in all-comers, particularly for patients who had an IVUS-defined optimal procedure, compared with angiography guidance. However, the benefit of IVUS guidance in coronary severe calcification still remains unknown in the modern DES era.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
864 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intravascular ultrasound guidance
Arm Type
Experimental
Arm Title
Angiography guidance
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Intravascular ultrasound
Intervention Description
Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
Intervention Type
Procedure
Intervention Name(s)
Angiography
Intervention Description
Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
Primary Outcome Measure Information:
Title
the rate of target-vessel failure at 12 months
Description
the composite of cardiovascular death, target-vessel myocardial infarction, and clinically driven target-vessel revascularization
Time Frame
12 months after indexed procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Silent ischemia, stable or unstable angina, non-ST-segment elevation myocardial infarction > 48 hours, or ST-segment elevation myocardial infarction > 7 days; De novo coronary lesion eligible for drug-eluting stent implantation; Target lesion with severe calcification; Exclusion Criteria: Age less than 18-year-old; Comorbidity with a life expectancy <12 months; Intolerant of antithrombotic therapy; Significant anemia, thrombocytopenia, or leucopenia; History of major hemorrhage (intracranial, gastrointestinal, and so on); Chronic total occlusion lesion not recanalized; Scheduled major surgery in the next 12 months; Left ventricular ejection fraction < 25%; Uremia dependent on dialysis treatment; Previous drug-eluting stent implantation in target vessel;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jun-Jie Zhang, MD
Phone
025-52271350
Email
jameszll@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shao-Liang Chen, MD
Organizational Affiliation
The First Affiliated Hospital with Nanjing Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaoliang Chen, MD
Phone
13605157029
Email
chmengx@126.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

IVUS-guided DES Implantation in Coronary Calcification

We'll reach out to this number within 24 hrs